The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Open accessAbstract
// Lukasz Skalniak 1, * , Krzysztof M. Zak 2, 3, * , Katarzyna Guzik 1 , Katarzyna Magiera 1 , Bogdan Musielak 1 , Magdalena Pachota 2, 3 , Bozena Szelazek 2, 3 , Justyna Kocik 1 , Przemyslaw Grudnik 2, 3 , Marcin Tomala 1 , Sylwia Krzanik 2, 3 , Krzysztof Pyrc 2, 3 , Alexander Dömling 4 , Grzegorz Dubin 2, 3 and Tad A. Holak 1 1 Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, 30-060 Krakow, Poland 2 Malopolska Centre of Biotechnology, Jagiellonian University, 30-387 Krakow, Poland 3 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Krakow, Poland 4 Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands * These authors contributed equally to this work Correspondence to: Tad A. Holak, email: holak@chemia.uj.edu.pl Grzegorz Dubin, email: grzegorz.dubin@uj.edu.pl Keywords: PD-1, PD-L1, small-molecules, immune checkpoint blockade, inhibitor Received: June 14, 2017 Accepted: July 25, 2017 Published: August 07, 2017 ABSTRACT Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years. In contrast, no small molecules with cellular activity have been reported so far. Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes. The two optimized small-molecule inhibitors of the PD-1/PD-L1 interaction, BMS-1001 and BMS-1166, developed by Bristol-Myers Squibb, bind to human PD-L1 and block its interaction with PD-1, when tested on isolated proteins. The compounds present low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1. As a result, BMS-1001 and BMS-1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1. We also determined the X-ray structures of the complexes of BMS-1001 and BMS-1166 with PD-L1, which revealed features that may be responsible for increased potency of the compounds compared to their predecessors. Further development may lead to the design of an anticancer therapy based on the orally delivered immune checkpoint inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,697
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“Prolonged exposure to PD-L1 leads to T cell exhaustion characterized by a sustained poor effector function [11, 12].”
BackgroundRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · cited 1×
“com/oncotarget recognize, but are unable to eradicate the cancer cells [13, 14].”
BackgroundCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
PD-L1 expression in human cancers and its association with clinical outcomes
Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787
Latchman, Y. E., Liang, S. C., Wu, Y., Chernova, T., Sobel, R. A., Klemm, M., Kuchroo, V. K., Freeman, G. J., & Sharpe, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307252101 · Cited by 636
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2015) · Structure · doi:10.1016/j.str.2015.09.010 · Cited by 531
Self-citationGenus- and species-specific identification of mycoplasmas by 16S rRNA amplification
van Kuppeveld, F. J., van der Logt, J. T., Angulo, A. F., van Zoest, M. J., Quint, W. G., Niesters, H. G., Galama, J. M., & Melchers, W. J. (1992) · Applied and Environmental Microbiology · doi:10.1128/aem.58.8.2606-2615.1992 · Cited by 503
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444 · cited 1×
“The inhibitory signal is provided by PD-L1, the ligand of PD1, which is naturally expressed on the antigen-presenting cells (APCs) and in a variety of tissues [8].”
BackgroundStructural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8730 · Cited by 422
Self-citationDavies, L. C., Heldring, N., Kadri, N., & Le Blanc, K. (2017) · Stem Cells · doi:10.1002/stem.2509 · Cited by 349
Frigola, X., Inman, B. A., Lohse, C. M., Krco, C. J., Cheville, J. C., Thompson, R. H., Leibovich, B., Blute, M. L., Dong, H., & Kwon, E. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0250 · Cited by 345
Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS
Krug, M., Weiss, M. S., Heinemann, U., & Mueller, U. (2012) · Journal of Applied Crystallography · doi:10.1107/s0021889812011715 · Cited by 306
Mueller, U., Förster, R., Hellmig, M., Huschmann, F. U., Kastner, A., Malecki, P., Pühringer, S., Röwer, M., Sparta, K., Steffien, M., et al. (2015) · The European Physical Journal Plus · doi:10.1140/epjp/i2015-15141-2 · Cited by 299
Docking essential dynamics eigenstructures
Mustard, D., & Ritchie, D. W. (2005) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20569 · Cited by 237
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Ostrand-Rosenberg, S., Horn, L. A., & Haile, S. T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401572 · Cited by 228
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
Brusa, D., Serra, S., Coscia, M., Rossi, D., D'Arena, G., Laurenti, L., Jaksic, O., Fedele, G., Inghirami, G., Gaidano, G., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.077537 · Cited by 222
Zhan, M.-M., Hu, X.-Q., Liu, X.-X., Ruan, B.-F., Xu, J., & Liao, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.011 · Cited by 188
Wang, L., Wang, H., Chen, H., Wang, W.-D., Chen, X.-Q., Geng, Q.-R., Xia, Z.-J., & Lu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5682 · Cited by 179
Status of the crystallography beamlines at PETRA III
Burkhardt, A., Pakendorf, T., Reime, B., Meyer, J. H., Fischer, P., Stuebe, N., Panneerselvam, S., Lorbeer, O., Stachnik, K., Warmer, M., et al. (2016) · The European Physical Journal Plus · doi:10.1140/epjp/i2016-16056-0 · Cited by 149
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)
Zarganes‐Tzitzikas, T., Konstantinidou, M., Gao, Y., Krzemień, D., Żak, K. M., Dubin, G., Holak, T. A., & Dömling, A. S. S. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1206527 · Cited by 105
Self-citationMonitoring the Effects of Antagonists on Protein−Protein Interactions with NMR Spectroscopy
D’Silva, L., Ozdowy, P., Krajewski, M., Rothweiler, U., Singh, M., & Holak, T. A. (2005) · Journal of the American Chemical Society · doi:10.1021/ja052143x · Cited by 88
Self-citationKrajewski, M., Rothweiler, U., D’Silva, L., Majumdar, S., Klein, C., & Holak, T. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070365v · Cited by 40
Self-citation
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 535
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131
Metadata
- Authors
- Skalniak, L., Zak, K. M., Guzik, K., Magiera, K., Musielak, B., Pachota, M., Szelazek, B., Kocik, J., Grudnik, P., Tomala, M., Krzanik, S., Pyrc, K., Dömling, A., Dubin, G., & Holak, T. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-08-07
- Volume
- 8
- Issue
- 42
- Pages
- 72167-72181
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2744859856
- Cited by
- 294
- References
- 41
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.